Abstract | BACKGROUND: PATIENTS AND METHODS: We conducted a bi-centric retrospective study comparing survival and toxicity according to the number of cycles of adjuvant temozolomide. RESULTS: Fifty-eight patients were included. All patients received radiotherapy with concomitant temozolomide. Thirty-eight patients received six cycles, while 20 received nine or more (median=14) cycles. The risk of recurrence was significantly higher in the group receiving six cycles compared to the other group. Prolonged treatment improved progression-free survival (p=0.03) and overall survival (p=0.01) in multivariate analysis without a significant increase in toxicity. CONCLUSION: Prolonged administration of temozolomide seems to improve progression-free and overall survival, without increased toxicity. Prospective studies in larger populations are needed to better-define the population to whom it can be proposed and its optimal duration.
|
Authors | Amélie Darlix, Cédric Baumann, Véronique Lorgis, François Ghiringhelli, Marie Blonski, Bruno Chauffert, Sonia Zouaoui, Catherine Pinelli, Fabien Rech, Patrick Beauchesne, Luc Taillandier |
Journal | Anticancer research
(Anticancer Res)
Vol. 33
Issue 8
Pg. 3467-74
(Aug 2013)
ISSN: 1791-7530 [Electronic] Greece |
PMID | 23898121
(Publication Type: Journal Article, Multicenter Study)
|
Chemical References |
- Adrenal Cortex Hormones
- Antineoplastic Agents, Alkylating
- Dacarbazine
- Temozolomide
|
Topics |
- Adolescent
- Adrenal Cortex Hormones
(therapeutic use)
- Adult
- Aged
- Antineoplastic Agents, Alkylating
(administration & dosage, adverse effects, therapeutic use)
- Brain Neoplasms
(drug therapy)
- Chemotherapy, Adjuvant
- Dacarbazine
(administration & dosage, adverse effects, analogs & derivatives, therapeutic use)
- Disease-Free Survival
- Female
- Glioblastoma
(drug therapy)
- Humans
- Male
- Middle Aged
- Recurrence
- Temozolomide
- Treatment Outcome
- Young Adult
|